AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

P3 Health Partners Inc.

$8.43 +$4.93 (+140.86%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$8.36
Day Range
$8.35$8.5
Year Range
$1.52$16.89
Market Cap
27.62M
AVG Volume
1.29M
Trailing/Forward PE
-0.26/-
PEG ratio
-0.01
Dividend Yield
-
Next Earnings Date
2026-11-12
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q21.5B
26 Q11.47B
25 Q41.46B
25 Q31.44B
25 Q21.46B
25 Q11.49B
24 Q41.5B
24 Q31.48B
24 Q21.4B
24 Q11.35B
Net Income (USD) · TTM
-150M-100M-50M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-98.44M
26 Q1-126.25M
25 Q4-147.95M
25 Q3-131.05M
25 Q2-145.97M
25 Q1-137.63M
24 Q4-135.85M
24 Q3-102.69M
24 Q2-69.48M
24 Q1-67.27M
Operating Income (USD) · TTM
-400M-300M-200M-100M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-148.63M
26 Q1-223.98M
25 Q4-270.3M
25 Q3-254.94M
25 Q2-317.7M
25 Q1-314.92M
24 Q4-320.66M
24 Q3-246.41M
24 Q2-173.25M
24 Q1-162.94M
EBITDA (USD) · TTM
-200M-150M-100M-50M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-82.31M
26 Q1-138.59M
25 Q4-181.86M
25 Q3-147.95M
25 Q2-199.2M
25 Q1-189.42M
24 Q4-197.76M
24 Q3-143.21M
24 Q2-75.23M
24 Q1-76.28M
Cash Flows (USD) · TTM
-150M-100M-50M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-130.4M
26 Q1-85.12M
25 Q4-91.12M
25 Q3-122.75M
25 Q2-129.96M
25 Q1-123.56M
24 Q4-110.13M
24 Q3-68.56M
24 Q2-53.91M
24 Q1-73.7M
EPS (USD) · TTM
-60-40-20024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-32.95
26 Q1-38.55
25 Q4-45.2
25 Q3-43
25 Q2-49.03
25 Q1-50.17
24 Q4-51.81
24 Q3-42.03
24 Q2-32.29
24 Q1-25.01
Expenses (USD) · TTM
-50M050M100M150MSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q2116.77M
26 Q1107.82M
25 Q4107.23M
25 Q3102.84M
25 Q2107.81M
25 Q1111.38M
24 Q4113.93M
24 Q3107.04M
24 Q2113.79M
24 Q1116.04M
Shares Outstanding (USD) · TTM
-6M-4M-2M0Buybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PIII Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-4.23M
26 Q1-4.82M
25 Q4-5.58M
25 Q3-4.48M
25 Q2-3.27M
25 Q1-1.81M
24 Q4-1.45M
24 Q3-1.45M
24 Q2-3.7M
24 Q1-3.7M
Employee Count
02004006002021202220242025
PIII Employee Count by quarter
PeriodEmployee Count
2025320
2024360
2022600
2021500
Free Cash Flow Yield
-2000%-1500%-1000%-500%0%med -451.77%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PIII Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-460.1%
Sep 26-414.83%
Aug 26-420.68%
Aug 26-376.2%
Aug 26-362.83%
Aug 26-223.56%
Jul 26-263.36%
Jul 26-269.11%
Jul 26-239.26%
Jul 26-264.16%
Jul 26-227.69%
Jun 26-228.9%
Jun 26-240.82%
Jun 26-211.68%
Jun 26-223.56%
May 26-212.55%
May 26-196.12%
May 26-229.3%
May 26-782.3%
May 26-947.84%
Apr 26-1051.96%
Apr 26-1068.14%
Apr 26-1093.37%
Apr 26-1080.61%
Mar 26-944.62%
Mar 26-1295.2%
Mar 26-1188.64%
Mar 26-1684.35%
Feb 26-1771.74%
Feb 26-1755.18%
Feb 26-1755.18%
Feb 26-1747.02%
Jan 26-1956.3%
Jan 26-1478.78%
Jan 26-1173.78%
Jan 26-1155.72%
Jan 26-1073.17%
Dec 25-1052.13%
Dec 25-911.67%
Dec 25-723.72%
Dec 25-716.81%
Nov 25-695.57%
Nov 25-657.81%
Nov 25-549.14%
Nov 25-502.88%
Oct 25-454.61%
Oct 25-449.98%
Oct 25-459.86%
Oct 25-432.37%
Oct 25-459.86%
Sep 25-407.56%
Sep 25-482.74%
Sep 25-462.54%
Sep 25-453.57%
Aug 25-477.53%
Aug 25-553.24%
Aug 25-586.7%
Aug 25-565.72%
Aug 25-515.69%
Jul 25-521.36%
Jul 25-573.42%
Jul 25-608.4%
Jul 25-594.09%
Jun 25-595.02%
Jun 25-606.45%
Jun 25-567.41%
Jun 25-572.55%
May 25-512.9%
May 25-519.22%
May 25-474.38%
May 25-388.72%
May 25-384.75%
Apr 25-378.72%
Apr 25-366.42%
Apr 25-445.49%
Apr 25-396%
Mar 25-391.42%
Mar 25-246.19%
Mar 25-241.97%
Mar 25-228.89%
Feb 25-224.05%
Feb 25-203.58%
Feb 25-184.11%
Feb 25-216.04%
Jan 25-235.25%
Jan 25-213.86%
Jan 25-205.56%
Jan 25-196.95%
Jan 25-170.74%
Dec 24-211.72%
Dec 24-214.95%
Dec 24-206.56%
Dec 24-183.31%
Nov 24-169.38%
Nov 24-198.8%
Nov 24-184.91%
Nov 24-105.24%
Nov 24-107.24%
Oct 24-97.21%
Oct 24-86.93%
Price to Sales
00.010.020.030.040.05med 0.02Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PIII Price to Sales by quarter
PeriodPrice to Sales
Sep 260.02
Sep 260.02
Aug 260.02
Aug 260.02
Aug 260.02
Aug 260.03
Jul 260.02
Jul 260.02
Jul 260.02
Jul 260.02
Jul 260.03
Jun 260.03
Jun 260.02
Jun 260.03
Jun 260.03
May 260.03
May 260.03
May 260.03
May 260.01
May 260.01
Apr 260.01
Apr 260.01
Apr 260.01
Apr 260.01
Mar 260.01
Mar 260.01
Mar 260.01
Mar 260.01
Feb 260
Feb 260
Feb 260
Feb 260
Jan 260
Jan 260.01
Jan 260.01
Jan 260.01
Jan 260.01
Dec 250.01
Dec 250.01
Dec 250.01
Dec 250.01
Nov 250.01
Nov 250.01
Nov 250.02
Nov 250.02
Oct 250.02
Oct 250.02
Oct 250.02
Oct 250.02
Oct 250.02
Sep 250.02
Sep 250.02
Sep 250.02
Sep 250.02
Aug 250.02
Aug 250.02
Aug 250.02
Aug 250.01
Aug 250.02
Jul 250.02
Jul 250.01
Jul 250.01
Jul 250.01
Jun 250.01
Jun 250.01
Jun 250.01
Jun 250.01
May 250.02
May 250.02
May 250.02
May 250.02
May 250.02
Apr 250.02
Apr 250.02
Apr 250.02
Apr 250.02
Mar 250.02
Mar 250.02
Mar 250.02
Mar 250.02
Feb 250.02
Feb 250.02
Feb 250.03
Feb 250.02
Jan 250.02
Jan 250.02
Jan 250.02
Jan 250.02
Jan 250.03
Dec 240.02
Dec 240.02
Dec 240.02
Dec 240.03
Nov 240.03
Nov 240.02
Nov 240.03
Nov 240.04
Nov 240.04
Oct 240.04
Oct 240.04
Price to Book
00.511.5med 0.19Aug 24Nov 24Feb 25Jun 25Sep 25Jan 26Sep 26
PIII Price to Book by quarter
PeriodPrice to Book
Sep 260.39
Sep 260.43
Aug 260.42
Aug 260.47
Aug 260.49
Mar 260.5
Mar 260.55
Mar 260.39
Feb 260.37
Feb 260.37
Feb 260.37
Feb 260.37
Jan 260.33
Jan 260.44
Jan 260.55
Jan 260.56
Jan 260.6
Dec 250.62
Dec 250.71
Dec 250.9
Dec 250.9
Nov 250.93
Nov 250.99
Nov 251.18
Nov 250.3
Oct 250.33
Oct 250.33
Oct 250.32
Oct 250.34
Oct 250.32
Sep 250.37
Sep 250.31
Sep 250.32
Sep 250.33
Aug 250.31
Aug 250.27
Aug 250.25
Aug 250.18
Aug 250.2
Jul 250.2
Jul 250.18
Jul 250.17
Jul 250.17
Jun 250.17
Jun 250.17
Jun 250.18
Jun 250.18
May 250.2
May 250.2
May 250.22
May 250.19
May 250.19
Apr 250.19
Apr 250.2
Apr 250.17
Apr 250.19
Mar 250.19
Mar 250.11
Mar 250.11
Mar 250.11
Feb 250.12
Feb 250.13
Feb 250.14
Feb 250.12
Jan 250.11
Jan 250.12
Jan 250.13
Jan 250.13
Jan 250.15
Dec 240.12
Dec 240.12
Dec 240.13
Dec 240.14
Nov 240.15
Nov 240.13
Nov 240.14
Nov 240.14
Nov 240.14
Oct 240.15
Oct 240.17
Oct 240.12
Oct 240.14
Sep 240.15
Sep 240.16
Sep 240.18
Sep 240.17
Aug 240.19
Aug 240.19
Aug 240.22
Aug 240.23
Aug 240.18
Jul 240.19
Jul 240.17
Jul 240.16
Jul 240.15
Jun 240.14
Jun 240.17
Jun 240.19
Jun 240.17
May 240.15
P3 Health Partners Inc.
PIII
Stockpicker

Video analysis: PIII

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PIII

Analyzing Molina Healthcare (NYSE:MOH) and P3 Health Partners (NASDAQ:PIII)

defenseworld.net · 9 Sep 2026

Analyzing Molina Healthcare (NYSE:MOH) and P3 Health Partners (NASDAQ:PIII)

P3 Health Partners (NASDAQ: PIII - Get Free Report) and Molina Healthcare (NYSE: MOH - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Volatility and Risk P3 Health Partners has

P3 Health Partners Q2 Earnings Call Highlights

marketbeat.com · 10 Aug 2026

P3 Health Partners Q2 Earnings Call Highlights

P3 Health Partners NASDAQ: PIII reported second-quarter adjusted EBITDA of $54 million and raised its full-year 2026 outlook, while noting that the quarterly result included $45 million of favorable payer settlements and prior-year development.

P3 Health Partners Inc. (PIII) Q2 2026 Earnings Call Transcript

seekingalpha.com · 10 Aug 2026

P3 Health Partners Inc. (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners Inc. (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners Announces Second Quarter 2026 Results

businesswire.com · 10 Aug 2026

P3 Health Partners Announces Second Quarter 2026 Results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2026. "Q2 demonstrates that the business is now executing according to our plan. We delivered $54 million of adjusted EBITDA, with the core business driving improved profitability quarter over quarter. Our results reflect the structural improvements.

P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call

businesswire.com · 21 Jul 2026

P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for second quarter 2026 on Monday, August 10, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Second Quarter 2026 Earnings C.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.